| Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2012: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2011: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2010: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Research Abstract |
To obtain basic information for clinical utilization of the PPARα agonist-utilizing therapy, we investigated the glomerular and tubular protective effects of PPARαactivation by using experimental animal model of kidney diseases. In 2011, we published that treatment of clofibrate, a representative PPARα agonist, exerts tubular protective effects against tubular damages caused by proteinuria. In 2012, we also reported that the maintenance of PPARα activation via PPARα agonist administration attenuated the disease activity of Thy1 glomerulonephritis, a most famous rat model of mesangium proliferative glomerulonephritis. These results suggest that renal PPARα activation exerts glomerular and tubular protective effect in various experimental model of kidney diseases.
|
